Last updated: 31 January 2020 at 5:31pm EST

John Amos Net Worth




The estimated Net Worth of John P. Amos is at least $1.68 Milione dollars as of 1 March 2019. Mr. Amos owns over 11,000 units of VIVUS stock worth over $802,147 and over the last 7 years he sold VVUS stock worth over $0. In addition, he makes $873,894 as Chief Executive Officer e Director at VIVUS.

Mr. Amos VVUS stock SEC Form 4 insiders trading

John has made over 5 trades of the VIVUS stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 11,000 units of VVUS stock worth $53,350 on 1 March 2019.

The largest trade he's ever made was buying 540,000 units of VIVUS stock on 15 May 2018 worth over $302,400. On average, John trades about 215,125 units every 37 days since 2018. As of 1 March 2019 he still owns at least 1,719,500 units of VIVUS stock.

You can see the complete history of Mr. Amos stock trades at the bottom of the page.





John Amos biography

John P. Amos serves as Chief Executive Officer, Director of the Company. Amos has served as the Chief Executive Officer and as a director of the Company since April 30, 2018. Mr. Amos served as the Executive Chairman of Willow Biopharma Inc., a biopharmaceutical company, from May 2017 to April 2018 when it was acquired by us. He served as the Chief Executive Officer of ORIX Healthcare Capital LLC, a private equity and venture capital investment company, from October 2012 to April 2017. Mr. Amos served as the Operating Partner and Portfolio Company Board Member of BioVeda China Fund, a financial investment company, from February 2008 to October 2012. He served as the Chief Executive Officer and President of the Oncology Therapeutics Network (acquired by McKesson Corporation in November 2007), a physician services company, from June 2005 to November 2007 and was a special advisor to McKesson Corporation, a public healthcare services company, from November 2007 to May 2008. Mr. Amos served as the President of Oncology Therapeutics Network of Bristol Myers Squibb, a publicly traded biopharmaceutical company, from June 2003 to May 2005. He held executive roles in finance and technology in McKesson Corporation from March 1995 to April 2003. From 1991 to 2003, he served in the United States Air Force and the California Air National Guard in Tactical Fighter Operations. Mr. Amos has previously served on the board of directors of TD2, Navigating Cancer, CITIC Pharmaceuticals, Aesyntix Health, Prodigy Health, Apollo Health Street, Quinian Health, Oncology Therapeutics Network and Matawan Pharmaceuticals. Mr. Amos served as a member of the Scientific Advisory Board at MD Anderson Cancer Center Institute for Applied Cancer Science (IACS) and was a health policy advisor to Governor Jeb Bush's 2016 Presidential Campaign. He has been appointed as a Trustee of the Global Leadership Council of the University of California, Davis Foundation.

What is the salary of John Amos?

As the Chief Executive Officer e Director of VIVUS, the total compensation of John Amos at VIVUS is $873,894. There are no executives at VIVUS getting paid more.



How old is John Amos?

John Amos is 53, he's been the Chief Executive Officer e Director of VIVUS since 2018. There are 7 older and 2 younger executives at VIVUS. The oldest executive at VIVUS, Inc. is Edward Kangas, 75, who is the Independent Director.

What's John Amos's mailing address?

John's mailing address filed with the SEC is 900 E Hamilton Ave Suite 550, Campbell, CA 95008, USA.

Insiders trading at VIVUS

Over the last 21 years, insiders at VIVUS have traded over $6,261,269 worth of VIVUS stock and bought 5,180,746 units worth $13,074,554 . The most active insiders traders include Tide Capital, Llc North Tid..., Alexander J Denner e Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of $35,394. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth $53,350.



What does VIVUS do?

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.



Complete history of Mr. Amos stock trades at VIVUS

Persona
Trans.
Transazione
Prezzo totale
John P. Amos
Chief Executive Officer
Acquistare $53,350
1 Mar 2019
John P. Amos
Chief Executive Officer
Acquistare $207,900
18 May 2018
John P. Amos
Chief Executive Officer
Acquistare $248,400
17 May 2018
John P. Amos
Chief Executive Officer
Acquistare $302,400
15 May 2018
John P. Amos
Chief Executive Officer
Acquistare $280,800
11 May 2018


VIVUS executives and stock owners

VIVUS executives and other stock owners filed with the SEC include: